XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Operating expenses:        
Research and development $ 131,096 $ 37,724 $ 390,382 $ 99,395
Acquired in-process research and development 0 0 0 15,007
General and administrative 103,115 20,654 479,117 45,982
Total operating expenses 234,211 58,378 869,499 160,384
Other income, net 2,418 4,578 9,085 8,949
Interest expense 0 (2,454) 0 (8,677)
Net loss $ (231,793) $ (56,254) $ (860,414) $ (160,112)
Net loss per share:        
Basic (in dollars per share) $ (0.31) $ (0.08) $ (1.16) $ (0.22)
Diluted (in dollars per share) $ (0.31) $ (0.08) $ (1.16) $ (0.22)
Weighted average common shares outstanding:        
Basic (in shares) 743,415,917 726,656,045 741,388,536 712,168,381
Diluted (in shares) 743,415,917 726,656,045 741,388,536 712,168,381
Other comprehensive gain (loss):        
Foreign currency translation adjustments $ 43 $ (155) $ (291) $ (175)
Reclassification of unrealized loss on short-term investments to other expense, net 0 0 0 3
Unrealized gain (loss) on short-term investments 0 346 (133) 312
Comprehensive loss $ (231,750) $ (56,063) $ (860,838) $ (159,972)